Key Clinical Points Essential Thrombocythemia Essential thrombocythemia is associated
with an increased risk of thrombosis and bleeding. Most patients with essential …

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α)
therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To …

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without
JAK inhibitor therapy | Blood | American Society of Hematology Skip to Main Content …

Abstract Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively
indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms …

The discovery of JAK2 V617F and the demonstration that BCR-ABL-negative
myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to …

The myeloproliferative neoplasms (MPNs) are clonal stem cell-derived diseases. This
chapter focuses on the subcategory of Philadelphia (Ph) chromosome-negative classical …

Abstract Purpose of Review The classic, chronic Philadelphia chromosome negative
myeloproliferative neoplasms (MPN)—essential thrombocythemia (ET), polycythemia vera …

Essential Thrombocythemia (ET) patients at high-risk of thrombosis require cytoreductive
treatment, typically with hydroxycarbamide. Many patients are resistant or intolerant to …

Abstract Purpose of Review With increased understanding of the pathobiology of
myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We …